Portage Biotech (PRTG) Stock Price, News & Analysis

Company Overview

Portage Biotech Inc. (NASDAQ: PRTG) is a clinical‐stage biotechnology company focused on building a diversified portfolio of innovative therapeutics targeting rare diseases and oncology indications. Leveraging an asset‐centric business model, Portage Biotech acquires and in‐licenses development‐stage compounds from academic institutions and biotechnology partners, then advances these assets through preclinical studies and early‐stage clinical trials within dedicated subsidiary entities.

The company’s pipeline spans small molecules, biologics and cell therapies, with programs directed at conditions such as myeloproliferative disorders, inherited blood disorders and solid tumor oncology. By organizing each development program under a stand‐alone subsidiary, Portage Biotech centralizes shared functions—such as regulatory affairs, manufacturing and clinical operations—while allowing focused teams to drive individual assets toward key value‐creating milestones.

Headquartered in New York, Portage Biotech maintains collaborations with research institutions in North America and Europe to expand its discovery footprint and accelerate candidate selection. The company’s management team brings experience from established biopharmaceutical and venture‐backed organizations, supporting a strategy of disciplined capital allocation and milestone‐driven advancement.

Portage Biotech’s approach aims to unlock value in early‐stage projects through targeted partnerships and efficient resource deployment, positioning the company to out‐license or co‐develop programs as they progress toward pivotal clinical readouts.

Key Stats

• Today's Range: $6.80 to $9.43
• 50-Day Range: $5.42 to $9.97
• 52-Week Range: $2.81 to $23.01
• Volume: 377,941 shs
• Average Volume: 56,380 shs
• Market Capitalization: $8.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRTG Stock Analysis - Frequently Asked Questions

How have PRTG shares performed this year?

Portage Biotech's stock was trading at $5.17 on January 1st, 2025. Since then, PRTG stock has increased by 47.6% and is now trading at $7.63.

How were Portage Biotech's earnings last quarter?

Portage Biotech Inc. (NASDAQ:PRTG) announced its quarterly earnings data on Tuesday, November, 26th. The company reported ($1.26) EPS for the quarter.

When did Portage Biotech's stock split?

Shares of Portage Biotech reverse split on Thursday, August 15th 2024.The 1-20 reverse split was announced on Tuesday, August 13th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, August 14th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Portage Biotech?

Shares of PRTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Portage Biotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Portage Biotech investors own include Meta Platforms (META), Alimera Sciences (ALIM), Angion Biomedica (ANGN), AirMedia Group (ANTE), Broadcom (AVGO), Barnwell Industries (BRN) and Crescent Biopharma (CBIO).

Company Calendar

• Last Earnings: 11/26/2024
• Today: 9/25/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRTG
• CIK: 1095435
• Web: www.portagebiotech.com
• Phone: 416-929-1806
• Fax: N/A
• Employees: 6
• Year Founded: 1973

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.02
• Quick Ratio: 2.02

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.79) per share
• Price / Book: -9.66

Miscellaneous

• Outstanding Shares: 1,050,000
• Free Float: 608,000
• Market Cap: $8.01 million
• Optionable: Optionable
• Beta: 0.25